Treventis Attending BIO 2022
Treventis will be at BIO next week -in person! Please ping us if you would like to meet in person or virtually. https://www.linkedin.com/in/chrisbarden/
Treventis attends RESI Nov 2021
Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year due to COVID-19). This conference is a prominent event for life sciences and medical technology companies looking to raise funds for the next stage of their company development. Treventis was proud to schedule meetings with […]
Treventis CSO Mark Reed gives invited lecture at Undruggable Leaders Forum
From September 15-16, 2021, the “Undruggable Leaders Forum” was a virtual meeting focused on new approaches to historically intractable targets. Treventis was proud to have CSO Mark Reed speak about “Identifying Druggable Active Sites in Misfolded Protein Targets,” which highlighted our proprietary, patented CCM discovery engine and the significant expertise we have build in assaying […]
Treventis attends RESI Partnering Week 2021
For the first time in several years, Treventis CEO Christopher Barden attended the Redefining Early Stage Investments (RESI) conference (held virtually this year due to COVID-19). This conference is a prominent event for life sciences and medical technology companies looking to raise funds for the next stage of their company development. Treventis was proud to […]
Treventis attends Virtual AAIC 2021
Treventis was well represented at the Alzheimer Association International Conference, running from Jul 26-30, 2021 (held virtually and in Denver, CO). CEO Christopher Barden and VP Research Marcia Taylor were delegates at the conference, the preeminent global annual gathering of Alzheimer’s researchers.
Treventis attends BIO Digital Conference
Treventis was represented at the BIO Digital International Convention (for a second year in a row, held virtually due to COVID-19) with more than 6,000 attendees and 55 countries represented. This conference hosts delegates passionate about creating new opportunities to partner and collaborate on innovative drug projects aimed at improving the lives of patients. This […]
Treventis presents at the Targeting Protein Misfolding Summit
Treventis VP Research Dr. Marcia Taylor was an invited speaker at the Targeting Protein Misfolding Summit, held virtually from March 15-17, 2021. Dr. Taylor presented a talk about our small molecule lead program in tauopathy and Alzheimer’s entitled “Use of in vitro and in vivo models to measure reduction of tau and amyloid beta oligomer.” […]
Treventis VP Research Marcia Taylor attends AD/PD 2021
Dr. Marcia Taylor was in attendance at the virtual AD/PD conference taking that took place on March 9-14, 2021. This event specializes in Alzheimer’s and Parkinson’s research and is ordinarily held in Europe each spring. Dr. Taylor noted that presented work demonstrated impressive advances in the field of plasma biomarkers for diagnosing and following course […]
Treventis scientists and advisors attend and present at ALS/MND 2020
Treventis scientists Drs. Christopher Barden and Ross Mancini and SAB member Dr. Janice Robertson attended the 31st Virtual International Symposium on ALS/MND that was held virtually on December 9-11th, 2020. Dr. Robertson’s Ph.D. student Marc Shenouda presented ‘Identification and validation of small molecules targeting the amyloidogenic core of TDP-43 as therapeutics for ALS/FTLD’ on identifying […]
Treventis attends Virtual AAIC 2020
Treventis was well represented at the Alzheimer Association International Conference, running from Jul 27-31, 2020 (originally scheduled for Amsterdam, the Netherlands, and converted to virtual format due to COVID-19). CEO Christopher Barden, VP Research Marcia Taylor, CSO Mark Reed, and Chief Medical Officer Dr. Donald Weaver were delegates at the conference, the preeminent global annual […]